InVivo Therapeutics Inc. is back on track with a second primate study, just a month after filing a lawsuit against its former contract research facility.
CEO Frank Reynolds told MassDevice in an email that the Cambridge, Mass.-based spinal tissue regeneration developer’s second primate study is already eight weeks in, having begun on August 20. Reynolds said the company went back to St. Kitts Biomedical Research Facility in St. Kitts, U.S. Virgin Islands, the site of its initial primate study back in 2007.